基于生物信息学分析STRA6在肺腺癌中的表达及意义

承德医学院学报 ›› 2025, Vol. 42 ›› Issue (5): 367-373.

基于生物信息学分析STRA6在肺腺癌中的表达及意义

左玉娟¹, 韩双花^1,2, 张冬^1,*

1.内蒙古科技大学包头医学院第一附属医院呼吸与危重症科,内蒙古包头 014010;
2.内蒙古科技大学包头医学院研究生院,内蒙古包头 014040

收稿日期:2024-08-12 出版日期:2025-10-10 发布日期:2025-10-23
通讯作者: *
基金资助:
内蒙古医学科学院公立医院科研联合基金科技项目（2023GLLH0206）; 包头医学院青年科技人才发展计划项目（BYJJ-DXX2022025）; 包头市卫生健康科技计划项目（wsjkkj009）

Analysis of The Expression and Significance of STRA6 in Lung Adenocarcinoma Based on Bioinformatics

ZUO Yu-juan¹, HAN Shuang-hua^1,2, ZHANG Dong^1,*

1. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, 014010, China;
2. Graduate School of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, 014040, China

Received:2024-08-12 Online:2025-10-10 Published:2025-10-23

摘要/Abstract

摘要： 目的利用生物信息学研究STRA6在肺腺癌（LUAD）中的表达及其在LUAD发生发展中的潜在作用。方法利用TCGA、GEO、LinkedOmicsKB、Kaplan-Meier Plotter、LinkedOmics、String、TISIDB等平台检测STRA6在LUAD中的表达、预后、相关基因功能富集、免疫细胞浸润、免疫检查点,并进行分析。结果 LUAD组织中STRA6的表达高于正常组织;STRA6可能通过免疫相关通路潜在地调节LUAD的发病机制,对LUAD细胞的增殖和迁移存在影响;STRA6可能通过免疫浸润发挥其致癌作用。结论 STRA6可作为LUAD的免疫治疗靶点,可能通过激活致癌途径和调节TME来驱动LUAD癌变。

关键词: STRA6, 肺腺癌, 免疫微环境, 生物信息学

Abstract: Objective To investigate the expression of stimulated by retinoic acid 6（STRA6） in LUAD and its potential role in the occurrence and development of LUAD using bioinformatics. Methods Platforms such as TCGA, GEO, LinkedOmicsKB, Kaplan - Meier Plotter, LinkedOmics, String, and TISIDB were utilized to detect and analyze the expression, prognosis, functional enrichment of related genes, immune cell infiltration, and immune checkpoints of STRA6 in LUAD. Results The expression of STRA6 in LUAD tissues was significantly higher than that in normal tissues. STRA6 may potentially regulate the pathogenesis of LUAD through immune-related pathways, affecting the proliferation and migration of LUAD cells. Moreover, STRA6 might exert its carcinogenic effect via immune infiltration. Conclusion STRA6 can serve as an immunotherapeutic target for LUAD, potentially driving LUAD carcinogenesis by activating oncogenic pathways and regulating TME.

Key words: STRA6, lung adenocarcinoma, immune microenvironment, bioinformatics

中图分类号:

R734.2

左玉娟, 韩双花, 张冬. 基于生物信息学分析STRA6在肺腺癌中的表达及意义[J]. 承德医学院学报, 2025, 42(5): 367-373.

ZUO Yu-juan, HAN Shuang-hua, ZHANG Dong. Analysis of The Expression and Significance of STRA6 in Lung Adenocarcinoma Based on Bioinformatics[J]. Journal of Chengde Medical University, 2025, 42(5): 367-373.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://tougao.cdmc.edu.cn:8088/CN/

http://tougao.cdmc.edu.cn:8088/CN/Y2025/V42/I5/367

参考文献

[1] Bray F, Laversanne M, Sung H, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] Chen Y, Clarke OB, Kim J, et al. Structure of the STRA6 receptor for retinol uptake[J]. Science, 2016, 353(6302): aad8266.
[3] Dhokia V, Macip S.A master of all trades - linking retinoids to different signalling pathways through the multi-purpose receptor STRA6[J]. Cell Death Discov, 2021, 7(1): 358.
[4] He W, Sun Y, Ge J, et al.STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma[J]. Front, Endocrinol(Lausanne), 2023, (14): 1076640.
[5] Yang F, Xu P, Yao S, et al.Up-regulation of STRA6 predicts poor prognosis and contributes to oxaliplatin resistance in colorectal cancer[J]. Pathol Res Pract, 2023, (243): 154352.
[6] Lin L, Xiao J, Shi L, et al.STRA6 exerts oncogenic role in gastric tumorigenesis by acting as a crucial target of miR-873[J]. J Exp Clin Cancer Res, 2019, 38(1): 452.
[7] Muñiz-Hernández S, Velázquez-Fernández JB, Díaz-Chávez J, et al.STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients[J]. Front Oncol, 2020, (10): 579561.
[8] 湛钊. HuR通过调控STRA6信号通路促进肝癌细胞的增殖、迁移及侵袭[D]. 贵阳:贵州医科大学,2021.
[9] Vasaikar SV, Straub P, Wang J, et al.LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Res, 2018, 46(1): 956-963.
[10] Ru B, Wong CN, Tong Y, et al.TISIDB: an integrated repository portal for tumor-immune system interactions[J]. Bioinformatics, 2019, 35(20): 4200-4202.
[11] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[12] Liu J, Li Y, Zhu X, et al.Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma[J]. Oncol Lett, 2019, 17(6): 4877-4890.
[13] Holling TM, Schooten E, van Den Elsen PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men[J]. Hum Immunol, 2004, 65(4): 282-290.
[14] Chae YK, Arya A, Iams W, et al.Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2018, 6(1): 39.
[15] Wagner M, Jasek M, Karabon L.Immune checkpoint molecules-inherited variations as markers for cancer risk[J]. Front Immunol, 2020, (11): 606721.
[16] Morad G, Helmink BA, Sharma P, et al.Hallmarks of response, resistance, and toxicity to immune checkpoint blockade[J]. Cell, 2021, 184(21): 5309-5337.
[17] Khan M, Arooj S, Wang H.NK cell-based immune checkpoint inhibition[J]. Front Immunol, 2020, (11): 167.
[18] Cao W, Chen HD, Yu YW, et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
[19] Schreiber RD, Old LJ, Smyth MJ.Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570.
[20] Huang D, Chen X, Zeng X, et al.Targeting regulator of G protein signaling 1 in tumorspecific T cells enhances their trafficking to breast cancer[J]. Nat Immunol, 2021, 22(7): 865-879.
[21] Wang S, Sun J, Chen K, et al.Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors[J]. BMC Med, 2021, 19(1): 140.
[22] Gertel S, Polachek A, Elkayam O, et al.Lymphocyte activation gene-3 (LAG-3) regulatory T cells: an evolving biomarker for treatment response in autoimmune diseases[J]. Autoimmun Rev, 2022, 21(6): 103085.